OxySure Systems Engages MZ Group for Investor Relations

Thu Mar 14, 2013 4:11pm EDT

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130314:nGNXUXJFWa

FRISCO, Texas and SYDNEY, March 14, 2013 (GLOBE NEWSWIRE) -- OxySure(R) Systems, Inc. (OTCQB:OXYS)
("OxySure," or the "Company"), a medical device innovator of life-saving, easy-to-use emergency
oxygen solutions with its "oxygen from powder" technology today announced that it has retained MZ
Group as its investor relations advisor in Australia, Brazil and the U.S.

MZ Group will assist OxySure with communicating its corporate, financial and investor-related
developments to shareholders and investors, as well as expanding its shareholder base,
particularly in North America.

Julian Ross, Chief Executive Officer of OxySure, explained, "This is an ideal time for us to
increase our investor outreach. Our flagship product, OxySure Model 615, the only over the counter
device in the U.S. cleared by the FDA for emergency respiratory applications, recently saved its
2,000thlife. Having signed several new distribution agreements over the past six months and
expanding our sales capability, we see an inflection point in our revenues on the horizon."

Ted Haberfield, President of MZ Group North America, stated, "We are extremely impressed with
OxySure's business model and growth opportunities. As the only U.S. FDA approved product based on
proprietary technologies, the value proposition is extremely compelling. Once they are able to
expand their installed base of systems across schools, restaurants and offices, they have a
tremendous opportunity to generate significant recurring cash flows. We look forward to
introducing their story to retail and institutional investors."

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design,
manufacture and distribution of specialty respiratory and medical solutions. The company pioneered
a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The
company owns numerous issued patents and patents pending on this technology which makes the
provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen
provision systems. OxySure's products improve access to emergency oxygen that affects the
survival, recovery and safety of individuals in several areas of need: (1) Public and private
places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac,
respiratory or general medical distress needing immediate help prior to emergency medical care
arrival; and (3) Those requiring immediate protection and escape from exposure situations or
oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to
Life or Health" (IDLH) environments. www.OxySure.com
http://www.globenewswire.com/newsroom/ctr?d=10025259&l=6&a=www.OxySure.com&u=http%3A%2F%2Fwww.oxysure.com%2F


About MZ Group 

MZ Group, subsidiary of @titude Global, a multinational company and the world's largest
independent global investor relations consulting firm, provides investor relations, corporate
communications, market intelligence, corporate governance and technology products and services.
Founded in 1999, MZ Group focuses on innovation and personalized services, supported by its
exclusive "one-stop-shop" business model. With offices in São Paulo, New York, Chicago, San Diego,
Vancouver, Hong Kong, Beijing, Shanghai, Taipei and Mumbai, MZ has approximately 350 professionals
who serve over 580 clients in 12 countries. For more information, please visit www.mzgroup.com
http://www.globenewswire.com/newsroom/ctr?d=10025259&l=8&a=www.mzgroup.com&u=http%3A%2F%2Fwww.mzgroup.com%2F
.

Forward-Looking Statements 

This release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Statements contained in this release that are not historical facts,
including, without limitation, statements that relate to the Company's expectations with regard to
the future impact on the Company's results from new products in development, may be deemed to be
forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should",
"anticipates", "likely", "believes" and words of similar import also identify forward-looking
statements. These statements are subject to risks and uncertainties. Forward-looking statements
are based on current facts and analyses and other information that are based on forecasts of
future results, estimates of amounts not yet determined and assumptions of management. Readers are
urged not to place undue reliance on the forward-looking statements, which speak only as of the
date of this release. Except as may be required under applicable law, we assume no obligation to
update any forward-looking statements in order to reflect any event or circumstance that may arise
after the date of this release. Additional information on risks and other factors that may affect
the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure
Systems, Inc. with the U.S. Securities and Exchange Commission.

Contact:

Investor Relations:
MZ North America
Ted Haberfield, President
Tel: +1-760-755-2716
Email: thaberfield@mzgroup.us
http://www.globenewswire.com/newsroom/ctr?d=10025259&l=12&a=thaberfield%40mzgroup.us&u=mailto%3Athaberfield%40mzgroup.us

Web: www.mzgroup.us
http://www.globenewswire.com/newsroom/ctr?d=10025259&l=12&a=www.mzgroup.us&u=http%3A%2F%2Fwww.mzgroup.us


This information was brought to you by Cision http://news.cision.com
http://www.globenewswire.com/newsroom/ctr?d=10025259&l=13&u=http%3A%2F%2Fnews.cision.com 

http://news.cision.com/oxysure-systems--inc-/r/oxysure-systems-engages-mz-group-for-investor-relations,c9385612
http://www.globenewswire.com/newsroom/ctr?d=10025259&l=14&u=http%3A%2F%2Fnews.cision.com%2Foxysure-systems--inc-%2Fr%2Foxysure-systems-engages-mz-group-for-investor-relations%2Cc9385612

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.